FDA Logo links to FDA home page Skip Navigation
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website
horizonal rule
Dockets Management

Back


2005D-0330
BKG 1
Volume 1

Reference List

Reference 1 - FDA Memorandum: Revised Guideline for the Collection of Platelets, Pheresis - 10/7/1988.

Reference 2 - FDA Recommendations and Licensure Requirements for Leukocyte-Reduced Blood Products, May 29, 1996.

Reference 3 - FDA Memorandum to Registered Blood and Source Plasma Establishments, Revision of FDA Memorandum of August 27,1982: Requirements for Infrequent Plasmapheresis Donors - 3/10/1995.

Reference 4 - FDA Guidance for Industry: Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods - Technical Correction February 2001 - 2/13/2001.

Reference 5 - Murphy S. Platelet storage for transfusion. Seminars in Hematology 1985 July; 22 (3): 165-77. Published Material

Reference 6 - Dumont LJ, VandenBroeke T. Seven-day storage of apheresis platelets: report of an in vitro study. Transfusion. 2003 Feb; 43 (2): 143-50. Published Material

Reference 7 - Blajchman MA. Incidence and significance of the bacterial contamination of blood components. Dev Biol 2002; 108: 59-67. Published Material

Reference 8 - Hillyer CD, Josephson CD, Blajchman, MA, Vostal JG, Epstein JS, Goodman JL. Bacterial contamination of blood components: risks, strategies, and regulation: Joint ASH and AABB Educational Session in Transfusion Medicine. Hematology 2003; 575-89. Published Material

Reference 9 - ASBPO Donor Deferral Criteria: Drugs and Medication Impact on Blood Donor Eligibility. www.tricare.osd.mil/asbpo/library/policies/downloads/medication_list.doc continued

Reference 10 - Patrono C, Coller B, Dalen JE, et al. Platelet-Active drugs. The relationships among dose, effectiveness, and side effects. Chest 2001 supplement; 119 (1): 39-63s. Published Material

Reference 11 - Federal Register, Proposed Rules, Vol. 50, No. 247, December 24, 1985. continued

Reference 12 - FDA Guideline on General Principles of Process Validation, May 1987, reprinted February 1993.

Reference 13 - FDA Guidance for Industry: Use of Sterile Connecting Devices in Blood Bank Practices 11/22/2000.

Reference 14 - FDA Guideline for Quality Assurance in Blood Establishments, July 11, 1995.

Reference 15 - Dumont LJ, Dzik WH, Rebulla P, et al. Practical guidelines for process validation and process control of white-cell reduced blood components: report of the Biomedical Excellence for Safer Transfusion (BEST) working party of the International Society of Blood Transfusion (ISBT). Transfusion 1996; 36: 11-20. Published Material

Reference 16 - CBER Device Clearances: http://www.fda.gov/cber/appr2002/2002approv.htm

Reference 17 - Brecher ME, Means N, Jere CS et al. Evaluation of an automated culture system for detecting bacterial contamination of platelets: an analysis with 15 contaminating organisms. Transfusion 2001 Apr; 41 (4): 477-482. Published Material

Reference 18 - McDonald CP, Roy A, Lowe P, et al. Evaluation of the BacT/Alert automated blood culture system for detecting bacteria and measuring their growth kinetics in leucodepleted and non-leucodepleted platelet concentrates. VOX Sang. 2001 Oct; 81(3): 154-60. Published Material

Reference 19 - Brecher ME, Heath DG, Hay SN, et al. Evaluation of a new generation of culture bottle using an automated bacterial culture system for detecting nine common contaminating organisms found in platelet components. Transfusion. 2002 Jun; 42(6): 774-9. Published Material

Reference 20 - FDA Draft Guidance for Industry: Biological Product Deviation Reporting for Licensed Manufacturers of Biological Products Other than Blood and Blood Components - 8/10/2001.

Reference 21 - Lazarus EF, Browning J, Norman J, Oblitas J, Leitman SF. Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations. Transfusion. 2001 June; 41: 756-761. Published Material

Reference 22 - Circular of Information for the Use of Human Blood and Blood Components. American Association of Blood Banks, America’s Blood Centers, American Red Cross, July, 2002.

Reference 23 - FDA Guidance for Industry: Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture - 8/7/2001.

Reference 24 - Glaz J, Naus J, Wallenstein S. Scan Statistics 2001. Springer Publishing. Published Material


Top | Back

Page last updated October 18, 2005 RSChorizonal rule
Dockets Home Page | Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

FDA/Dockets Management